Ocuphire Pharma Hits New 52-Week High of $5.10, Up 180.59%

Ocuphire Pharma, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 5.10 on March 9, 2026. This achievement marks a remarkable increase of 180.59% over the past year, significantly outperforming the S&P 500, which has seen a gain of 17.78% during the same period. With a market capitalization of USD 234 million, Ocuphire Pharma operates in a competitive industry characterized by innovation and rapid advancements. Despite its current loss-making status, the company continues to attract attention due to its performance metrics. The stock's price-to-book ratio stands at 39.18, indicating a premium valuation relative to its book value. Investors may note that the stock's journey from a 52-week low of USD 0.65 to its current high reflects substantial growth and volatility. As Ocuphire Pharma continues to navigate the dynamic landscape of pharmaceuticals and biotechnology, its recent performance underscores the potential for further developments in the sector.